ALS-FUS mutations cause abnormal PARylation and histone H1.2 interaction, leading to pathological changes
Hafiza Alirzayeva, Rute Loureiro, Seda Koyuncu, Franziska Hommen, Yara Nabawi, William Zhang, Thien T.P. Dao, Markus Wehrmann, Hyun Ju Lee, David Vı́lchez
Abstract
The majority of severe early-onset and juvenile cases of amyotrophic lateral sclerosis (ALS) are caused by mutations in the FUS gene, resulting in rapid disease progression. Mutant FUS accumulates within stress granules (SGs), thereby affecting the dynamics of these ribonucleoprotein complexes. Here, we define the interactome of the severe mutant FUS P525L variant in human induced pluripotent stem cell (iPSC)-derived motor neurons. We find increased interaction of FUS P525L with the PARP1 enzyme, promoting poly-ADP-ribosylation (PARylation) and binding of FUS to histone H1.2. Inhibiting PARylation or reducing H1.2 levels alleviates mutant FUS aggregation, SG alterations, and apoptosis in human motor neurons. Conversely, elevated H1.2 levels exacerbate FUS-ALS phenotypes, driven by the internally disordered terminal domains of H1.2. In C. elegans models, knockdown of H1.2 and PARP1 orthologs also decreases FUS P525L aggregation and neurodegeneration, whereas H1.2 overexpression worsens ALS-related changes. Our findings indicate a link between PARylation, H1.2, and FUS with potential therapeutic implications.